A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. Issue 2 (December 2015) - Hecht, J; Raman, Steven; Sze, Daniel; Lockhart, A; Moss, Rebecca; Liu, Kate; Chou, Jeffrey; Reid, Tony